Literature DB >> 431034

C-cell hyperplasia and medullary thyroid carcinoma in the rat. An immunohistochemical and ultrastructural analysis.

R A DeLellis, G Nunnemacher, W R Bitman, R F Gagel, A H Tashjian, M Blount, H J Wolfe.   

Abstract

Medullary thyroid carcinoma (MTC) is a distinctive neoplasm which is derived from the calcitonin-producing intrathyroidal C-cell system and which develops commonly in untreated rats of various strains. Thyroid glands of Long-Evans rats ranging in age from 3 months to 3 years showed a spectrum of C-cell proliferative abnormalities. As compared to 3-month-old control rats, thyroids from 9- to 12-month-old animals exhibited mild diffuse C-cell hyperplasia (CCH). Thyroids from animals ranging from 1 to 3 years of age exhibited progressively more severe C-cell abnormalities including severe diffuse CCH, nodular CCH, and/or MTC. In contrast to the normal basal serum calcitonin levels in controls and in animals with mild diffuse CCH, animals with severe diffuse CCH, nodular CCH, or MTC had elevated basal serum calcitonin values. Nodular CCH was characterized by the replacement and enlargement of individual follicles by C-cells. Larger foci of nodular CCH were characterized by similar changes in multiple adjacent follicles or by an irregular expansion of individual follicles. MTC was characterized by penetration of the follicular basal lamina by C-cells with extension into the adjacent thyroid stroma. In addition to the high incidence of thyroidal C-cell abnormalities, diffuse and/or nodular parathyroid hyperplasia was commonly found. There was no evidence of chronic renal failure in these animals, and the serum calcium levels were within normal limits. Although the stimulus for the initial C-cell proliferation remains unknown, the appearance of MTC is preceded by relatively prolonged phases of CCH. These findings are essentially identical with those noted in human familial MTC and indicate that the rat provides a useful model system for studying the regulation of C-cell proliferation during the processes of neoplastic development and progression.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 431034

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

1.  Quantitative changes in the frequency and distribution of the C-cell population in the rat thyroid gland with age.

Authors:  I Martín-Lacave; E Conde; C Montero; H Galera-Davidson
Journal:  Cell Tissue Res       Date:  1992-10       Impact factor: 5.249

2.  Calcitonin secretion, C cell differentiation and proliferation during the spontaneous development of murine medullary thyroid carcinoma.

Authors:  S Lausson; G E Volle; M Bourges; E Pidoux; C Borrel; G Milhaud; M S Moukhtar; A Jullienne; F Treilhou-Lahille
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  The influence of phospholipid membranes on bovine calcitonin secondary structure and amyloid formation.

Authors:  Steven S-S Wang; Theresa A Good; Dawn L Rymer
Journal:  Protein Sci       Date:  2005-05-09       Impact factor: 6.725

Review 4.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

5.  Expression of somatostatin mRNA and peptides in C-cell tumours of the thyroid gland in Han Wistar rats.

Authors:  Andrew Pilling; Stewart Jones; John Turton
Journal:  Int J Exp Pathol       Date:  2004-02       Impact factor: 1.925

6.  Medullary thyroid carcinoma in female BALB/c mice. A report of 3 cases with ultrastructural, immunohistochemical, and transplantation data.

Authors:  M J Van Zwieten; C H Frith; A L Nooteboom; H J Wolfe; R A Delellis
Journal:  Am J Pathol       Date:  1983-02       Impact factor: 4.307

7.  Somatostatin-like immunoreactivity in rat thyroid. Age-associated S-cell hyperplasia.

Authors:  K Kakudo; K Uematsu; K Sakurai; M Suehiro; M Fukuchi
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.